TIE2

TIE2 Overview

English NameTEK receptor tyrosine kinaseApproved Drugs4
Drugs in Clinical Trials9Target SynonymEC:2.7.10.1,Endothelial Tyrosine Kinase,Tyrosine-protein kinase receptor TEK,Tunica interna endothelial cell kinase,Angiopoietin-1 receptor,p140 TEK,Tyrosine kinase with Ig and EGF homology domains-2,TEK,TEK Receptor Tyrosine Kinase,Tyrosine-Protein Kinase Receptor TIE-2,TEK Tyrosine Kinase, Endothelial,VMCM1,VMCM,TIE2,Venous Malformations, Multiple Cutaneous And Mucosal,CD202b Antigen,EC 2.7.10.1,CD202B,GLC3E,TIE-2,HTIE2,Receptor, TIE-2,EC 2.7.10
Highest Development StageApproved
English NameTEK receptor tyrosine kinase
Target SynonymEC:2.7.10.1,Endothelial Tyrosine Kinase,Tyrosine-protein kinase receptor TEK,Tunica interna endothelial cell kinase,Angiopoietin-1 receptor,p140 TEK,Tyrosine kinase with Ig and EGF homology domains-2,TEK,TEK Receptor Tyrosine Kinase,Tyrosine-Protein Kinase Receptor TIE-2,TEK Tyrosine Kinase, Endothelial,VMCM1,VMCM,TIE2,Venous Malformations, Multiple Cutaneous And Mucosal,CD202b Antigen,EC 2.7.10.1,CD202B,GLC3E,TIE-2,HTIE2,Receptor, TIE-2,EC 2.7.10
Approved Drugs4
Drugs in Clinical Trials9
Highest Development StageApproved

TIE2 Product List

  • Product Category

    Protein (4)

  • Product Status

    Launched (4)

  • Species

    Human (2)Cynomolgus (1)Mouse (1)

  • Tag

    Fc Tag (1)His Tag (3)

  • Conjugate

    Unconjugated (4)

TIE2 Background

Tyrosine-protein kinase that acts as cell-surface receptor for ANGPT1, ANGPT2 and ANGPT4 and regulates angiogenesis, endothelial cell survival, proliferation, migration, adhesion and cell spreading, reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence. Has anti-inflammatory effects by preventing the leakage of proinflammatory plasma proteins and leukocytes from blood vessels. Required for normal angiogenesis and heart development during embryogenesis. Required for post-natal hematopoiesis. After birth, activates or inhibits angiogenesis, depending on the context. Inhibits angiogenesis and promotes vascular stability in quiescent vessels, where endothelial cells have tight contacts. In quiescent vessels, ANGPT1 oligomers recruit TEK to cell-cell contacts, forming complexes with TEK molecules from adjoining cells, and this leads to preferential activation of phosphatidylinositol 3-kinase and the AKT1 signaling cascades. In migrating endothelial cells that lack cell-cell adhesions, ANGT1 recruits TEK to contacts with the extracellular matrix, leading to the formation of focal adhesion complexes, activation of PTK2/FAK and of the downstream kinases MAPK1/ERK2 and MAPK3/ERK1, and ultimately to the stimulation of sprouting angiogenesis. ANGPT1 signaling triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Signaling is modulated by ANGPT2 that has lower affinity for TEK, can promote TEK autophosphorylation in the absence of ANGPT1, but inhibits ANGPT1-mediated signaling by competing for the same binding site. Signaling is also modulated by formation of heterodimers with TIE1, and by proteolytic processing that gives rise to a soluble TEK extracellular domain. The soluble extracellular domain modulates signaling by functioning as decoy receptor for angiopoietins. TEK phosphorylates DOK2, GRB7, GRB14, PIK3R1; SHC1 and TIE1.

TIE2 Synonyms

TIE2,Tie-2,TEK,VMCM, VMCM1,CD202b,Angiopoietin-1 receptor

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
PegevongitideAV-001Phase 2 ClinicalAnges Inc, Sunnybrook Health Sciences Centre, Vasomune Therapeutics IncBrain Injuries; Coronavirus Disease 2019 (COVID-19); Pneumonia; Pneumonia, Viral; Respiratory Distress Syndrome, Adult; Respiratory Tract Infections
Details
Merestinib5OGS5K699E; LY-2801653Phase 2 ClinicalEli Lilly And CompanyBiliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours
Details
TrebananibAMG-386; 20060439Phase 2 ClinicalAmgen Inc, Takeda Pharmaceutical Co LtdAdenocarcinoma, Clear Cell; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hemangiosarcoma; Kidney Diseases; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Renal Insufficiency; Sarcoma; Sarcoma, Endometrial Stromal; Solid tumours; Uterine Neoplasms
Details
IGT-303IGT-303Phase 2 ClinicalIngenia Therapeutics IncRenal Insufficiency, Chronic
Details
IGT-427IGT-427Phase 2 ClinicalIngenia Therapeutics IncDiabetic macular oedema; Retinal Diseases; Wet Macular Degeneration
Details
GersizangitideAXT-107Phase 2 ClinicalAsclepiX Therapeutics IncDiabetic macular oedema; Macular Degeneration
Details
CEP-11981ESK-981; CEP-11981; SSR-106462; BOL-303213XPhase 2 ClinicalSanofiAdenoma, Islet Cell; Bone metastases; Carcinoma, Adenosquamous; Carcinoma, Neuroendocrine; Gastrointestinal Neoplasms; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Details
PMC-403PMC-403Phase 1 ClinicalPharmabcineCapillary Leak Syndrome; Macular Degeneration; Solid tumours; Wet Macular Degeneration
Details
QBH-196QBH-196Phase 1 ClinicalShenyang Pharmaceutical UniversitySolid tumours; Stomach Neoplasms
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
RegorafenibDAST; BAY-73-4506ApprovedBayer AGStivarga, ResihanceUnited StatesColorectal NeoplasmsBayer Healthcare Pharmaceuticals Inc2012-09-27Adenocarcinoma; Adenoma; Bile Duct Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Islet Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastrinoma; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Glucagonoma; Hemangiosarcoma; Insulinoma; Leukemia, Myeloid, Acute; Liver Neoplasms; Lung Neoplasms; Melanoma; Meningioma; Neoplasm Metastasis; Neoplasms; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Rectal Neoplasms; Sarcoma; Sarcoma, Ewing; Solid tumours; Somatostatinoma; Stomach Neoplasms; Thymoma; Thyroid Neoplasms
Details
RipretinibDCC-2618ApprovedDeciphera PharmaceuticalsQinlock, 擎乐United StatesGastrointestinal Stromal TumorsDeciphera Pharmaceuticals Llc2020-05-15Gastrointestinal Stromal Tumors; Mastocytosis, Systemic; Neoplasms
Details
Ponatinib HydrochlorideAP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534ApprovedAriad英可欣, IclusigUnited StatesLeukemia, Myelogenous, Chronic; Precursor Cell Lymphoblastic Leukemia-LymphomaAriad Pharmaceuticals Inc2012-12-14Adenocarcinoma of Lung; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Common Bile Duct Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic-Phase; Leukemia, Myelomonocytic, Chronic; Lymphoma; Medullary thyroid cancer (MTC); Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid Neoplasms
Details
Cabozantinib S-malateXL-184; BMS-907351; RO7047650; RO-7047650ApprovedExelixis IncCometriq, CabometyxUnited StatesThyroid Neoplasms; Carcinoma, NeuroendocrineExelixis Inc2012-11-29Adenocarcinoma, Clear Cell; Adenocarcinoma, Follicular; Adenoma, Islet Cell; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Astrocytoma; Bile Duct Neoplasms; Bone metastases; Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Adenosquamous; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Glioblastoma; Glioma; Gliosarcoma; Hepatic Insufficiency; Hepatoblastoma; HIV Infections; Kidney Neoplasms; Leiomyosarcoma; Leukemia, Myeloid, Acute; Lymphoma; Medullary thyroid cancer (MTC); Melanoma; Meningioma; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroendocrin
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8